

MEDICAL POLICY	Genetic Testing: Diagnostic Evaluation of Interstitial Lung Disease (All Lines of Business Except Medicare)	
Effective Date: 1/1/2021  <div style="text-align: right;">1/1/2021</div>	Section: GT	Policy No: 445
	Medical Policy Committee Approved Date: 5/2020, 12/2020	
Medical Officer	Date	

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

APPLIES TO:

All lines of business except Medicare

BENEFIT APPLICATION

Medicaid Members

Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

POLICY CRITERIA

The use of genomic sequencing classifiers for diagnostic evaluation of interstitial lung disease (i.e., Envisia® Genomic Classifier by Veracyte, Inc.) are considered **investigational and are not covered**.

Link to [Policy Summary](#)

MEDICAL POLICY	Genetic Testing: Diagnostic Evaluation of Interstitial Lung Disease (All Lines of Business Except Medicare)
-----------------------	------------------------------------------------------------------------------------------------------------------------

CPT/HCPCS CODES

All Lines of Business Except Medicare	
Not Covered	
81554	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP])
Unlisted Codes	
All unlisted codes will be reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is billed related to services addressed in this policy then it will be denied as not covered .	
81479	Unlisted molecular pathology procedure

DESCRIPTION

Interstitial Lung Disease (ISD)

Interstitial lung disease is characterized by a large group of disorders, which causes progressive scarring of lung tissue.¹ This scarring eventually affects the ability to breathe and get enough oxygen into the bloodstream. The primary signs and symptoms include shortness of breath at rest or aggravated by exertion and dry cough. Risk factors include age, exposure to environmental toxins, uncontrolled gastroesophageal reflux disease (GERD), smoking, radiation and chemotherapy. Some types of interstitial lung disease include:

- Interstitial pneumonia
- Idiopathic pulmonary fibrosis
- Nonspecific interstitial pneumonitis
- Hypersensitivity pneumonitis

According to the Mayo Clinic, identifying and determining the cause of interstitial lung disease is challenging.¹ The symptoms of ISD mimic a wide range of medical conditions, and these must be ruled out before making a definitive diagnosis. Treatments include medications, pulmonary rehabilitation, and oxygen therapy.

Envisia® Genomic Classifier

According to the manufacturer, the Envisia® Genomic Classifier is the first commercially available genomic test to improve the diagnosis of idiopathic pulmonary fibrosis (IPF).² The test is intended for patients undergoing evaluation for interstitial lung disease, including IPF. Envisia uses RNA whole-

MEDICAL POLICY	Genetic Testing: Diagnostic Evaluation of Interstitial Lung Disease (All Lines of Business Except Medicare)
-----------------------	--------------------------------------------------------------------------------------------------------------------------------

transcriptome sequencing and a machine learning algorithm to interrogate 190 genes in bronchial biopsy samples. This allows Envisia to identify the genomic pattern and differentiate IPF from other interstitial lung diseases without surgical lung biopsy.

REVIEW OF EVIDENCE

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of genomic classifiers for the diagnostic evaluation of interstitial lung disease. Below is a summary of the available evidence identified through February of 2020.

In 2020, Hayes conducted a genetic test evaluation report assessing the Envisia® Genomic Classifier (Veracyte®).³ Hayes identified three studies evaluating Envisia. Only two of these studies addressed the analytic validity, one study evaluated the clinical validity, and no studies reported on the clinical utility of the test.

Studies demonstrated the analytic and clinical validity of the Envisia genomic classifier; however, no studies were conducted to demonstrate changes in patient management or patient outcomes. The overall body of evidence was rated very low due to the limited number of studies and data to support the test. Hayes concluded with the following rating:

D2 (insufficient evidence): for use of the Envisia Genomic Classifier that uses RNA sequencing to assess the genomic profile of transbronchial biopsy samples and uses machine learning to identify the genomic pattern for usual interstitial pneumonia in order to distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases in combination with high-resolution computed tomography and clinical information during the diagnostic workup without the need for surgical lung biopsy.³

CLINICAL PRACTICE GUIDELINES

No evidence-based clinical practice guidelines were identified which address the use of genomic classifiers for the diagnostic evaluation of interstitial lung disease.

POLICY SUMMARY

There is insufficient published evidence to support the medical necessity of genomic classifiers for the diagnostic evaluation of interstitial lung disease. Additional studies are required to demonstrate changes in patient management and patient outcomes due to the Envisia® genomic classifier. Additionally, no clinical practice guidelines recommend the use of genomic classifiers for evaluation of interstitial lung disease.

MEDICAL POLICY	Genetic Testing: Diagnostic Evaluation of Interstitial Lung Disease (All Lines of Business Except Medicare)
-----------------------	--------------------------------------------------------------------------------------------------------------------------------

INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

REGULATORY STATUS

Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

REFERENCES

1. Mayo Clinic: Interstitial Lung Disease. 2017; <https://www.mayoclinic.org/diseases-conditions/interstitial-lung-disease/symptoms-causes/syc-20353108>. Accessed 4/3/2020.
2. Varacyte: Envisia Genomic Classifier. <https://www.veracyte.com/our-products/envisia>. Accessed 4/2/2020.
3. Hayes Genetic Testing Evaluation: Envisia Genomic Classifier (Veracyte). 2020; <https://evidence.hayesinc.com/report/gte.envisia4708>. Accessed 4/3/2020.